This verified cross-border patent dispute closed in May 2026 under USITC Investigation No.337-TA-1444, targeting a Chinese medical equipment manufacturer that built a nested offshore corporate structure to cover up its mainland operating entity and avoid patent litigation liabilities. The real domestic manufacturer is anonymised as Jiangsu Ruida Medical Technology Co., Ltd., a Nanjing-based enterprise producing disposable surgical irrigation devices, while the patent plaintiff is US medical tech firm Aardvark Medical Inc., holder of five valid US invention patents covering minimally invasive surgical flushing components.
Since early 2024, Ruida Medical mass-produced surgical devices that fully fell within the technical protection scope of the plaintiff’s US patents, then exported finished products to the US, EU and UAE medical supply distributors. To block patent holders and US customs authorities from tracing back to its Chinese headquarters, the enterprise established a three-tier offshore hiding system covering sales subjects, customs consignees and capital settlement carriers, with zero disclosure of Ruida’s corporate identity in all cross-border trade documents and overseas e-commerce platform archives.
Three core concealment mechanisms adopted to hide the Chinese parent entity: First, register three independent shell companies in the British Virgin Islands, Singapore and Hong Kong; all Amazon medical store operators, sea freight consignees and overseas payment receiving accounts use these offshore entities, with Ruida’s name removed from all business registration materials. Second, sign nominal OEM outsourcing agreements with the three offshore shells, falsely recording Ruida as a third-party foundry without actual control, while internal OA records prove Ruida holds 100% equity of all offshore entities and dominates all R&D, production and sales decisions. Third, apply for anonymous offshore bank settlement accounts to split export revenue; all sales funds were transferred to Ruida’s domestic corporate account after layered cross-border remittance, with transfer notes labelled “technical consulting service fees” to mask infringing product sales proceeds.
The patent plaintiff first discovered infringing surgical instruments on Amazon US medical channels in March 2025. Cease-and-desist letters sent to the displayed Singapore shell company received automated rejection replies, and US cross-border e-commerce platforms refused to provide the actual Chinese manufacturer’s information on grounds of merchant privacy protection. The plaintiff retained US IP litigators to launch formal discovery proceedings before the US International Trade Commission, aiming to pierce the offshore shell veil and identify the concealed Chinese patent infringer.
After USITC administrative law judge approved the full evidence subpoena application in January 2026, the plaintiff’s legal team obtained complete production records, cross-border logistics manifests and enterprise internal operation data, confirming multiple severe intentional infringements violating 19 U.S.C. §1337 and China’s Patent Law Article 71. First, Ruida Medical copied all core technical parameters of the plaintiff’s patented irrigation valve assembly without signing any patent licensing contract or conducting freedom-to-operate (FTO) patent risk assessment. Third-party technical appraisal institutions entrusted by USITC completed comparative testing, verifying 99.2% overlap between the internal structural design of Ruida’s infringing devices and the technical solutions recorded in the five US invention patents, with only trivial plastic shell size adjustments made to bypass preliminary customs product screening.
Second, the enterprise’s R&D department deliberately erased all patent comparison records and technical modification archives from internal servers. Staff operation logs extracted from Ruida’s Nanjing office cloud storage showed that technical supervisors issued written internal instructions requiring engineers to delete all prior-art patent retrieval files after product prototype development, eliminating written proof of knowing patent protection boundaries. Under US patent judicial practice, deliberate destruction of technical evidence constitutes aggravated infringement circumstances and supports higher statutory compensation.
Third, Ruida continued large-scale export of infringing products after receiving two customs detention notices in late 2025. US Customs detained three batches of its surgical equipment shipped via the Hong Kong shell consignee in October and November 2025; instead of suspending production, Ruida transferred production orders to two cooperative foundries in Anhui, changed sea freight ports to Dubai Jebel Ali Port, and continued supplying UAE local medical wholesalers through BVI shell trading companies. Customs statistics submitted to USITC proved that over 86,000 sets of infringing medical devices were exported to the UAE and North America between February 2024 and April 2026, forming a stable transnational supply chain independent of the trademark and copyright cases mentioned in previous articles, with fully separated fact chains and legal logic.
The core litigation difficulty of this case lay in breaking the three-layer offshore shell shielding architecture to confirm Ruida Medical’s direct tort liability. USITC launched three independent evidence collection channels to verify the actual control relationship between offshore entities and the Nanjing domestic manufacturer, and all evidence obtained underwent notarisation and cross-verification.First evidence channel: Subpoena cloud service providers for offshore shell backend operation logs. Lawyers issued legal subpoenas to AWS Singapore and Hong Kong cloud operators, acquiring IP login records of all offshore company sales and settlement backends. All daily order management, production scheduling and financial reconciliation operations logged fixed IP segments belonging to Nanjing Telecom, and the bound office device serial numbers matched Ruida Medical’s R&D and sales department fixed workstations, directly linking overseas infringing business to the Chinese headquarters.
Second evidence channel: Judicial audit of cross-border capital flow records from payment institutions. USITC ordered HSBC Singapore, Standard Chartered Hong Kong and domestic Chinese commercial banks to disclose full transfer records of the three offshore shells. All net profits generated by infringing medical equipment exports were regularly remitted to Ruida’s domestic public account through encrypted cross-border intermediate accounts; certified financial auditors confirmed the total remittance amount perfectly matched the export quantity recorded in UAE and US customs clearance declarations.
Third evidence channel: Inter-department internal communication archives of the Chinese enterprise. Discovery procedures retrieved thousands of WeChat group chat screenshots, enterprise OA memos and board meeting minutes of Ruida’s overseas sales management team. Senior management explicitly instructed staff to “separate domestic production subjects from overseas sales shells to avoid US patent lawsuits” and “never fill in Jiangsu Ruida’s corporate name in any foreign customs filing documents”. These internal written records became decisive subjective malice evidence proving the enterprise actively built an identity concealment system to evade patent legal sanctions.
In the final determination issued by USITC on May 9, 2026, the commission fully upheld all relief requests filed by patent owner Aardvark Medical, and issued targeted sanctions aiming at Ruida’s offshore entity concealment infringement strategy. First, the commission ruled that Jiangsu Ruida Medical Technology Co., Ltd. is the actual primary patent infringer, and the BVI, Singapore and Hong Kong shell companies are merely instrumental entities set up solely to isolate liability; all import bans, compensation obligations and administrative fines shall be borne jointly and severally by Ruida and its three offshore affiliated companies.
Second, aggravated statutory damages and administrative fines due to intentional concealment and repeated export infringement. Under US patent law, single invention patent statutory compensation ranges from USD 2,000 to USD 1,500,000; for commercial infringers adopting multi-layer offshore hiding structures to evade supervision and continuing infringement after customs interception, USITC can impose maximum penalty standards. Considering Ruida’s complete identity shielding framework, long-term large-volume exports to the UAE market and intentional destruction of technical evidence, the commission ordered total statutory compensation of USD 3.82 million for five infringed invention patents, plus an additional administrative fine of USD 650,000 for evidence tampering and offshore liability evasion. The defendant was also ordered to fully cover the plaintiff’s cross-border attorney fees, technical appraisal fees and evidence collection costs totalling USD 418,000.
Third, two permanent import restriction orders were issued: a Limited Exclusion Order barring all infringing surgical irrigation devices manufactured by Ruida and its offshore shells from entering US territory permanently; a Cease-and-Desist Order prohibiting Ruida from establishing any new anonymous offshore trading entities to sell patent-infringing medical products within 8 years. For cross-border enforcement of assets located in China, the plaintiff’s legal team submitted the USITC formal ruling to Nanjing Intermediate People’s Court in June 2026 in accordance with China-US IP judicial cooperation mechanisms. The Chinese court completed judicial recognition of the foreign patent judgment in mid-July 2026, froze Ruida’s production workshop equipment, inventory assets and corporate bank accounts, and forced the enterprise to complete full compensation payment within 60 working days. Meanwhile, all case materials were filed with the China National Intellectual Property Administration, and Ruida was added to the national patent infringement credit blacklist, restricting its cross-border customs export declaration qualification for four years.
This case has been selected by WIPO as a typical cross-border patent compliance reference case for Chinese medical device exporters, exposing severe legal risks of the widely adopted offshore shell identity hiding model among domestic manufacturers supplying Gulf countries including the UAE. Most export enterprises mistakenly believe layered overseas registered companies can insulate domestic parent entities from patent litigation liabilities, yet this ruling fully proves transnational IP law enforcement authorities can pierce multi-level offshore shielding structures through server logs, financial audits and internal corporate documents to trace the actual Chinese manufacturing infringer.
Three mandatory compliance rectification requirements for Chinese enterprises exporting medical, electronic and industrial equipment to the UAE: First, implement full FTO patent pre-review for all core product technical solutions before mass production and export, and retain complete patent search reports and licensing contracts for all imported or referenced third-party patented technologies. Second, truthfully disclose actual domestic manufacturer information on all cross-border customs declarations, overseas platform merchant filings and foreign trade sales contracts, abandoning anonymous offshore privacy shielding services designed to hide domestic corporate identity. Third, standardise cross-border financial bookkeeping and capital remittance classification, strictly prohibiting labelling product export profits as technical consulting fees or service income to avoid financial records being identified as malicious patent liability evasion evidence in cross-border litigation.
For enterprises already holding multiple offshore shell companies for overseas sales, international IP lawyers recommend completing comprehensive internal risk remediation within 90 days: fully audit all export product technical solutions to remove goods falling within third-party patent protection scopes, supplement formal patent licensing agreements for products with potential infringement risks, and record the complete equity control chain between offshore shells and domestic parent manufacturers in notarised legal documents to reduce the risk of being identified as liability-isolating instrumental entities in future patent disputes.
1. https://www.usitc.gov/investigations/337-TA-1444 (USITC Official Case Archive for Investigation No.337-TA-1444)
2. https://www.cnipa.gov.cn/col/col3652/index.html (CNIPA 2025 National Patent Infringement Typical Cases Database)
3. https://www.wipo.int/wipolex/en/text/7817 (WIPO Lex Official Full English Text of China Patent Law)
4. https://patft.uspto.gov/ (USPTO US Invention Patent Full-text Retrieval Official Portal)
